Pharmaceutical follow-up for patients on rituximab therapy for non-Hodgkin lymphoma: what is the evidence?
- 369 Downloads
Background Introduction of the monoclonal antibody rituximab to chemotherapy regimens has substantially improved disease-free and overall survival in patients with non-Hodgkin lymphomas (NHL). The short-term safety of this drug has been widely reported, but there are few data on long-term safety, which suggests that these patients require prolonged follow-up. Aim of the review To review the literature on follow-up models, with a focus on the safety of rituximab therapy for diffuse large B-cell lymphoma and follicular lymphoma. Method The Cochrane Library, Embassy, Lilacs, Medline, and Scirus databases were searched for systematic reviews and randomized controlled trials. Furthermore, textbooks and journals on pharmaceutical care and institutional websites were searched for patient management recommendations. The outcomes were follow-up models and grade 3, 4, and 5 adverse reactions. Results Five systematic reviews and eight clinical trials or updates describing patient follow-up or reporting adverse reactions were identified. Only one systematic review and seven clinical trials reported follow-up routines for patients receiving rituximab, including information on staging, frequency of reassessment, and laboratory tests, as well as pre-infusion care and management of acute or delayed adverse reactions. Five systematic reviews and four clinical trials reported data on statistically significant adverse reactions (fever, leukopenia, infection). Four guidelines or institutional protocols for treatment and follow-up were identified, as well as seven studies describing experiences in the implementation of pharmaceutical care for oncology patients, but none were specifically focused on follow-up of patients receiving rituximab for NHL. Conclusion Although some systematic reviews and clinical trials contain guidance on follow-up of patients receiving rituximab for NHL, there are no validated strategies for systematic follow-up of these patients with a focus on safety. As there are few data on long-term safety profile of these novel treatments, monitoring strategies should be developed and implemented to ensure safe and optimized use of drugs recently added to the therapeutic arsenal of clinical oncology.
KeywordsAdverse drug reaction Drug-related problem Hematology Non-Hodgkin’s lymphoma Oncology Pharmaceutical care Pharmacovigilance Rituximab
To the care team oncology and hematology at the Hospital Nossa Senhora da Conceição, Grupo Hospitalar Conceição, Ministry of Health, Brazil.
Brazilian National Health Surveillance Agency (Anvisa).
Conflicts of interest
- 1.Australian Cancer Network Diagnosis and Management of Lymphoma Guidelines Working Party. Guidelines for the diagnosis and management of lymphoma. Sydney: The Cancer Council Australia and Australian Cancer Network; 2005.Google Scholar
- 3.Rituximabe no tratamento do linfoma difuso de grandes células B [Rituximab in the treatment of diffuse large B cell lymphoma]. Brazilian Bulletin on Health Technology Assessment (BRATS) [serial on the Internet]. 2009;4(10); Available from: http://126.96.36.199/rebrats/brats.php.
- 8.Freedman A, Friedberg J. Initial treatment of follicular lymphoma. 2013 [cited 2013 03/31/2013]; Available from: http://www.uptodate.com.
- 9.Ghielmini M, Schmitz SF, Cogliatti SB, Pichert G, Hummerjohann J, Waltzer U, et al. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly × 4 schedule. Blood. 2004;103(12):4416–23.PubMedCrossRefGoogle Scholar
- 10.Knight C, Hind D, Brewer N, Abbott V. Rituximab (MabThera) for aggressive non-Hodgkin’s lymphoma: systematic review and economic evaluation. Health Technol Assess. 2004;8(37):iii, ix–xi, 1–82.Google Scholar
- 11.van Oers MH, Klasa R, Marcus RE, Wolf M, Kimby E, Gascoyne RD, et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood. 2006;108(10):3295–301.PubMedCrossRefGoogle Scholar
- 13.MabThera® (rituximab). F. Hoffmann-La Roche; 2013 [cited 2013 03/31/2013]; Available from: http://www.dialogoroche.com.br/content/dam/dialogo/pt_br/Bulas/M/MabThera/mabthera-profissional-20120119.pdf.
- 14.van Oers MH, Van Glabbeke M, Giurgea L, Klasa R, Marcus RE, Wolf M, et al. Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin’s lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study. J Clin Oncol. 2010;28(17):2853–8.PubMedCrossRefGoogle Scholar
- 15.Ivama A, Noblat L, de Castro M, de Oliveira N, Jaramillo N, Rech N. Consenso Brasileiro de Atenção Farmacêutica [Brazilian Consensus on Pharmaceutical Care]. 1st ed. Brasília: Organização Pan-Americana da Saúde; 2002.Google Scholar
- 19.Schulz H, Bohlius J, Skoetz N, Trelle S, Kober T, Reiser M, Dreyling M, Herold M, Schwarzer G, Hallek M, Engert A. Chemotherapy plus Rituximab versus chemotherapy alone for B-cell non-Hodgkin’s lymphoma. Cochrane Database Syst Rev. 2007;(4). doi: 10.1002/14651858.CD003805.pub2.
- 21.Vidal L, Gafter-Gvili A, Leibovici L, Shpilberg O. Rituximab as maintenance therapy for patients with follicular lymphoma. Cochrane Database Syst Rev. 2009;(2). doi: 10.1002/14651858.CD006552.pub2.
- 22.Martí-Carvajal AJ, Cardona AF, Lawrence A. Interventions for previously untreated patients with AIDS-associated non-Hodgkin’s lymphoma. Cochrane Database Syst Rev. 2009;(3):CD005419.Google Scholar
- 23.Coiffier B, Thieblemont C, Van Den Neste E, Lepeu G, Plantier I, Castaigne S, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d’Etudes des Lymphomes de l’Adulte. Blood. 2010;116(12):2040–5.PubMedCrossRefGoogle Scholar
- 24.Feugier P, Van Hoof A, Sebban C, Solal-Celigny P, Bouabdallah R, Fermé C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol. 2005;23(18):4117–26.PubMedCrossRefGoogle Scholar
- 25.Kaplan LD, Lee JY, Ambinder RF, Sparano JA, Cesarman E, Chadburn A, et al. Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010. Blood. 2005;106(5):1538–43.PubMedCrossRefGoogle Scholar
- 26.Pfreundschuh M, Schubert J, Ziepert M, Schmits R, Mohren M, Lengfelder E, et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol. 2008;9(2):105–16.PubMedCrossRefGoogle Scholar
- 27.CHOP-R. Ontario: Juravinski Cancer Centre; 2008 [cited 2013 03/12/2013]; Available from: http://www.jcc.hhsc.ca/workfiles/PHARMACY/HE-CHOP-R.pdf.
- 28.Non-Hodgkin’s Lymphomas. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Version 1.2013 ed: National Comprehensive Cancer Network; 2012.Google Scholar
- 29.Guidance on the administration of rituximab infusions. London: The North London Cancer Network; 2009 [cited 2013 03/31/2013]; Available from: http://www.nlcn.nhs.uk/BChemoGui.
- 30.Guidelines for the management of tumour lysis syndrome. London: The North London Cancer Network; 2010 [cited 2013 03/31/2013]; Available from: http://www.nlcn.nhs.uk/BChemoGui.
- 33.Wong S, Gray E. Clinical pharmacy services in oncology clinics. J Oncol Pharm Pract. 1999;5(1):49–54.Google Scholar
- 39.Eisenach M. Pharmaceutical counseling. In: Pharmacy GSoO, editor. QuapoS 4: quality standard for the oncology pharmacy service with commentary. Hamburg: European Society of Oncology Pharmacy (ESOP); 2009. p. 452.Google Scholar
- 40.Castro M, Fuchs F, Ferreira M. Reflexão sobre a prática e o ensino do seguimento farmacoterapêutico de pacientes [Reflection on the practice and teaching of patients pharmacotherapeutic follow-up]. In: Storpirtis S, Mori A, Yochiy A, Ribeiro E, Porta V, editors. Farmácia Clínica e Atenção Farmacêutica [Clinical pharmacy and pharmaceutical care]. Rio de Janeiro: Guanabara Koogan; 2008.Google Scholar
- 41.Witzel M. Aspectos conceituais e filosóficos da Assistência Farmacêutica, Farmácia Clínica e Atenção Farmacêutica [Conceptual and philosophical aspects of pharmaceutical services, clinical pharmacy and pharmaceutical care]. In: Storpirtis S, Mori A, Yochiy A, Ribeiro E, Porta V, editors. Farmácia Clínica e Atenção Farmacêutica [Clinical pharmacy and pharmaceutical care]. Rio de Janeiro: Guanabara Koogan; 2008.Google Scholar
- 43.Moreira R. Suggesting pharmacotherapeutical follow-up in chronic myeloid leukemia: a methodological approach model. Braz J Oncol. 2009;55(4):375–8.Google Scholar
- 44.Omoti C, Agada L. Compliance with chemotherapy in adult leukemia patients in Benin City, Nigeria. Seguimiento Farmacoterapéutico. 2005;3(1):1–9.Google Scholar
- 48.Williamson S. Management of oral anticancer therapies. Pharm J. 2008;281(7522):399–402.Google Scholar
- 51.Roscoe J, Goransson E, Slancar M, Smith J, Taylor S, Tyson S. A multidisciplinary approach to ensure safety in the prescribing and administration of chemotherapy. J Oncol Pharm Pract. 2000;6(2):60–3.Google Scholar